Tema Heart & Health ETF (NASDAQ:HRTS) Sees Large Drop in Short Interest

Tema Heart & Health ETF (NASDAQ:HRTS) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 2,508 shares, a decline of 50.8% from the July 30th total of 5,095 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average daily volume of 3,207 shares, the short-interest ratio is presently 0.8 days.

Tema Heart & Health ETF Stock Performance

Shares of NASDAQ:HRTS traded down $0.42 during midday trading on Friday, reaching $37.64. The company had a trading volume of 3,797 shares, compared to its average volume of 5,984. Tema Heart & Health ETF has a 1-year low of $29.45 and a 1-year high of $38.87. The firm has a market cap of $56.08 million, a price-to-earnings ratio of 22.06 and a beta of 0.63. The company has a fifty day simple moving average of $36.89 and a two-hundred day simple moving average of $35.15.

Institutional Trading of Tema Heart & Health ETF

A number of hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new stake in Tema Heart & Health ETF during the fourth quarter valued at about $27,000. JPMorgan Chase & Co. purchased a new position in shares of Tema Heart & Health ETF in the second quarter worth approximately $63,000. XML Financial LLC acquired a new stake in shares of Tema Heart & Health ETF during the second quarter valued at approximately $223,000. Citadel Advisors LLC acquired a new stake in shares of Tema Heart & Health ETF during the third quarter valued at approximately $243,000. Finally, Anson Capital Inc. acquired a new stake in shares of Tema Heart & Health ETF during the second quarter valued at approximately $297,000.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.